<?xml version="1.0" encoding="UTF-8"?>
<p id="Par9">During the SARS outbreak in 2003, an animal study revealed that recombinant human IFN-α2b spray can prevent SARS-CoV infection in Rhesus monkey model by inhibiting virus infection and replication [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Further population study revealed that recombinant human IFN-α2b spray can effectively reduce the infection rate of respiratory syncytial virus, influenza virus, adenovirus and SARS-CoV [
 <xref ref-type="bibr" rid="CR12">12</xref>, 
 <xref ref-type="bibr" rid="CR13">13</xref>]. 
 <italic>The Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards </italic>(
 <italic>the fourth edition</italic>) and 
 <italic>Diagnosis, treatment and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement</italic> also listed IFN-α atomization as a choice of treatment for 2019-nCoV pneumonia [
 <xref ref-type="bibr" rid="CR14">14</xref>].
</p>
